In a trial with more than one presentation or use, how should safety reporting be conducted?

• A. Be consolidated across all presentations
• B. Not be required for additional uses
• C. Be required only for the primary presentation
• D. Be conducted separately for each presentation

Answer: (D)

When a trial uses more than one presentation or use of the product, safety reporting must be conducted separately for each presentation. Each presentation can have a distinct safety profile due to differences in dosage, route of administration, formulation, excipients, or labeling. If safety data were consolidated across all presentations, important signals unique to a specific presentation could be masked or misattributed, making it harder to assess the true risk associated with that particular form or use. Therefore, adverse events and SUSARs should be linked to the exact presentation involved, and safety reports should be generated and reviewed per presentation. The trial’s safety plan and regulatory requirements support this per-presentation approach to ensure accurate attribution and timely risk management. Reporting for other uses or only the primary presentation would miss relevant safety information and is not consistent with best practice.